Evaluation of Treated & Untreated Stroke

Status Completed

Clinical Trial Summary

This project will investigate the evolution of treated and untreated stroke in patients recruited from the collaborative brain stroke program between NINDS, CC, and Suburban Hospital. The study will use anatomical and functional imaging techniques with emphasis on the acute and subacute stage (less than one month) of the disease.

As the availability of new therapeutic options for the management of acute brain stroke increases, the need to define the evolution of the disease becomes paramount, particularly as therapeutic windows, defined by known and perhaps yet undiscovered parameters, may exist. Defining these parameters will be based on state-of-the-art imaging technology with the potential of clarifying the division between ischemia (reversible damage) and infarction (irreversible). Measures of lesion size and distribution along with vascular morphology, diffusion, perfusion, flow-related, and metabolic measures will be obtained over time. We foresee these measurements will significantly develop our understanding of cerebral ischemia and introduce diagnostic and quantitative tools to guide therapy and measure its efficacy.

Clinical Trial Description

This project will investigate the evolution of treated and untreated stroke in patients recruited from the collaborative brain stroke program between NINDS, CC, and Suburban Hospital. The study will use anatomical and functional imaging techniques with emphasis on the acute and subacute stage (less than one month) of the disease.

As the availability of new therapeutic options for the management of acute brain stroke increases, the need to define the evolution of the disease becomes paramount, particularly as therapeutic windows, defined by known and perhaps yet undiscovered parameters, may exist. Defining these parameters will be based on state-of-the-art imaging technology with the potential of clarifying the division between ischemia (reversible damage) and infarction (irreversible). Measures of lesion size and distribution along with vascular morphology, diffusion, perfusion, flow-related, and metabolic measures will be obtained over time. We foresee these measurements will significantly improve our understanding of cerebral ischemia and introduce diagnostic and quantitative tools to guide therapy and measure its efficacy. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001840
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	February 1999
Completion date	July 2001

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05477238` - Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls	N/A
Completed	`NCT00046293` - ReoPro and Retavase to Treat Acute Stroke	Phase 2
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Completed	`NCT01116544` - Treatment of Chronic Stroke With AMES + EMG Biofeedback	N/A
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Active, not recruiting	`NCT02563886` - Electrically Assisted Movement Therapy	N/A
Recruiting	`NCT02446730` - Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome	Phase 4
Completed	`NCT02141932` - Pocket-size Cardiovascular Ultrasound in Stroke	N/A
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Recruiting	`NCT02557737` - Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities	Phase 3
Recruiting	`NCT01769326` - Influence of Timing on Motor Learning	N/A
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Completed	`NCT01423201` - Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
Completed	`NCT01656876` - The Effects of Mirror Therapy on Upper Extremity in Stroke Patients	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Withdrawn	`NCT00573092` - Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs	N/A
Completed	`NCT00542256` - tDCS and Physical Therapy in Stroke	N/A
Completed	`NCT00377689` - Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke	Phase 2
Recruiting	`NCT00166751` - Sonographic Assessment of Laryngeal Elevation	N/A
Terminated	`NCT00120289` - Niacin Plus Statin to Prevent Vascular Events	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Treated and Untreated Stroke

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms